Skip to content
bioprocess.updates
AdvertisementHouse ad · Perfusion seriesPerfusion, explained: a three-part seriesRead the seriesBioprocessUpdates

Cell & Gene TherapyBrief

Minaris adds a dedicated viral vectors business unit, effective 1 October 2026

The CGT CDMO now runs cell therapies, viral vectors and advanced testing as three business units. Viral vector CDMO services are centralized at its Philadelphia site.

Primary source Minaris: Minaris Evolves Business Model with Addition of Dedicated Viral Vectors Business Unit

Illustration: Minaris adds a dedicated viral vectors business unit, effective 1 October 2026
Illustration, AI-generated

Minaris, a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and contract testing company, announced on 29 September 2026 that it is adding a dedicated Viral Vectors business unit. The company now operates through three units: Cell Therapies, Viral Vectors and Advanced Testing. According to the release, the new model is effective October 1, 2026, so it is already in force. This is an organizational change, and the release does not announce new capacity or new equipment.

The three units

  • Minaris Cell Therapies covers autologous and allogeneic programs. The release cites 25+ years of cell therapy development and manufacturing. Services run from process development and technology transfer to current good manufacturing practice (GMP) manufacturing, quality systems, and scale-up or scale-out strategies, supported by sites in the US, Europe and Asia.
  • Minaris Viral Vectors covers viral vector technologies, development and manufacturing for gene therapy and genetically modified cell therapy programs, including in vivo lentiviral programs. The release cites 10+ years of experience in viral vector process and analytical development, technology transfer, GMP manufacturing and scalable production strategies. It uses a portfolio of plasmids and cell lines developed through OXGENE.
  • Minaris Advanced Testing provides GMP biosafety, viral clearance, potency and analytical testing for biologics, vaccines and advanced therapies. The release cites 40 years of experience.

Viral vector CDMO services are centralized at the Philadelphia site, while OXGENE is based in the UK. Customers may engage with one unit or several, depending on program needs.

The company’s stated reasons for the change

The release says the industry is expanding toward in vivo gene therapies, which require viral vector development, scalable manufacturing strategies, analytical and biosafety testing, and a strong quality and regulatory mindset. It says the structure is designed to strengthen customer engagement, accelerate decision making and support more efficient execution across the company’s global network. The release gives no metrics, such as lead times or capacity, to measure those aims against.

For context, the release states that Minaris was formed through the 2025 acquisitions of Minaris Regenerative Medicine and WuXi Advanced Therapies (formerly the WuXi AppTec Philadelphia site) by the US private equity firm Altaris.

Released: every figure in this piece was checked against the linked primary source before publication. Released is our editorial check, not a regulatory status.

Written by BIOT, an AI system. How we work Report an error

More from Cell & Gene Therapy